Alliance Pharma expanded their leadership team by four, bringing on board a new Chief Operating Officer in Jean Pierre Boutrand, Chief Commercial Officer in Vito Saccente, Chief Financial Officer in Glenn Weber, and Susan Woolley as Chief People Officer.
Paradigm Clinical Research announced the appointment of Kurt Mussina as CEO. Additonally, the company announced growth on its executive leadership team, bringing on board Travis Milnes as chief financial officer and Amy Henderson as head of clinical operations.
Sharp, has appointed Robert Feltz as Director, Analytical and Formulation Services and Michael MacNeir as Vice President, Global Business Development.
Trialbee announced the addition of Jo Holton as VP of Global Sales to their company.
TransCelerate announced that, previously COO, Janice Chang, has been appointed Chief Executive Officer.
Recbio Technology Co. contracted OCT Clinical to carry out its phase III clinical study for a SARS-CoV-2 vaccine.
Stayble Therapeutics and OCT Clinical reported that the last patient has been enrolled in the ongoing phase IIb clinical trial of STA363.
dMed |Clinipace announced that it is changing its corporate name to Caidya (pronounced KAY-dee-uh).
CluePoints celebrated its tenth anniversary.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.